Methotrexate in the combination therapy of juvenile idiopathic arthritis
The paper discusses whether biological agents (BAs) may be used as monotherapy. The combination of different BAs and methotrexate (MTX) allows a good result in patients with juvenile idiopathic arthritis refractory to standard antirheumatic therapy. The efficiency of this therapy meets the ACRpedi50...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/849 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242037284503552 |
|---|---|
| author | E. S. Zholobova М. N. Nikolaeva S. N. Chebysheva A. V. Meleshkina O. Yu. Loskutova L. A. Galstyan E. Yu. Afonina |
| author_facet | E. S. Zholobova М. N. Nikolaeva S. N. Chebysheva A. V. Meleshkina O. Yu. Loskutova L. A. Galstyan E. Yu. Afonina |
| author_sort | E. S. Zholobova |
| collection | DOAJ |
| description | The paper discusses whether biological agents (BAs) may be used as monotherapy. The combination of different BAs and methotrexate (MTX) allows a good result in patients with juvenile idiopathic arthritis refractory to standard antirheumatic therapy. The efficiency of this therapy meets the ACRpedi50 criteria in 80–90% of patients; one third of patients can achieve the inactive stage of the disease. When BAs are administered, the frequency of use of nonsteroidal anti-inflammatory drugs and glucocorticoids is reduced. In only 15% of patients, MTX can be discontinued during the first year of therapy with BA, significantly more frequently with tocilizumab. |
| format | Article |
| id | doaj-art-3b74946d3ea34ea1bcf1b58bd5499016 |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2018-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-3b74946d3ea34ea1bcf1b58bd54990162025-08-20T03:59:56ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2018-09-011239810210.14412/1996-7012-2018-3-98-1022114Methotrexate in the combination therapy of juvenile idiopathic arthritisE. S. Zholobova0М. N. Nikolaeva1S. N. Chebysheva2A. V. Meleshkina3O. Yu. Loskutova4L. A. Galstyan5E. Yu. Afonina6University Children's Hospital; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaUniversity Children's Hospital; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaUniversity Children's Hospital; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaUniversity Children's Hospital; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaUniversity Children's Hospital; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaUniversity Children's Hospital; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaUniversity Children's Hospital; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaThe paper discusses whether biological agents (BAs) may be used as monotherapy. The combination of different BAs and methotrexate (MTX) allows a good result in patients with juvenile idiopathic arthritis refractory to standard antirheumatic therapy. The efficiency of this therapy meets the ACRpedi50 criteria in 80–90% of patients; one third of patients can achieve the inactive stage of the disease. When BAs are administered, the frequency of use of nonsteroidal anti-inflammatory drugs and glucocorticoids is reduced. In only 15% of patients, MTX can be discontinued during the first year of therapy with BA, significantly more frequently with tocilizumab.https://mrj.ima-press.net/mrj/article/view/849methotrexatebiological therapyjuvenile idiopathic arthritis |
| spellingShingle | E. S. Zholobova М. N. Nikolaeva S. N. Chebysheva A. V. Meleshkina O. Yu. Loskutova L. A. Galstyan E. Yu. Afonina Methotrexate in the combination therapy of juvenile idiopathic arthritis Современная ревматология methotrexate biological therapy juvenile idiopathic arthritis |
| title | Methotrexate in the combination therapy of juvenile idiopathic arthritis |
| title_full | Methotrexate in the combination therapy of juvenile idiopathic arthritis |
| title_fullStr | Methotrexate in the combination therapy of juvenile idiopathic arthritis |
| title_full_unstemmed | Methotrexate in the combination therapy of juvenile idiopathic arthritis |
| title_short | Methotrexate in the combination therapy of juvenile idiopathic arthritis |
| title_sort | methotrexate in the combination therapy of juvenile idiopathic arthritis |
| topic | methotrexate biological therapy juvenile idiopathic arthritis |
| url | https://mrj.ima-press.net/mrj/article/view/849 |
| work_keys_str_mv | AT eszholobova methotrexateinthecombinationtherapyofjuvenileidiopathicarthritis AT mnnikolaeva methotrexateinthecombinationtherapyofjuvenileidiopathicarthritis AT snchebysheva methotrexateinthecombinationtherapyofjuvenileidiopathicarthritis AT avmeleshkina methotrexateinthecombinationtherapyofjuvenileidiopathicarthritis AT oyuloskutova methotrexateinthecombinationtherapyofjuvenileidiopathicarthritis AT lagalstyan methotrexateinthecombinationtherapyofjuvenileidiopathicarthritis AT eyuafonina methotrexateinthecombinationtherapyofjuvenileidiopathicarthritis |